Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.
Advanced Non-squamous NSCLC
DRUG: Anlotinib plus Pemetrexed|DRUG: Pemetrexed
Proportion of patients alive and progression free at 6 months (APF6), the number (%) of patients who are alive and progression free per RECIST 1.1 at 6 months after randomization per Kaplan-Meier estimate of progression free survival at 6 months., Estimated to be from baseline up to 2 years
Progression Free Survival(PFS), the time from randomization until the date of objective disease progression (RECIST 1.1) or death (by any cause in the absence of progression), Estimated to be from baseline up to 2 years|Overall Survival(OS), the time from randomization to death from any cause, Estimated to be from baseline up to 2 years|Disease Control Rate(DCR), the total proportion of patients who demonstrate a response(complete responses + partial responses + stable disease ) to treatment, Estimated to be from baseline up to 2 years|Objective Response Rate(ORR), the total proportion of patients who demonstrate a response(complete responses + partial responses) to treatment, Estimated to be from baseline up to 2 years
Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET.